|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
104,690,000 |
Market
Cap: |
103.12(B) |
Last
Volume: |
259,279 |
Avg
Vol: |
765,410 |
52
Week Range: |
$692.45 - $993.95 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 150 |
Guru Rank Value : 6.9 |
Guru Occurances : 2 |
|
|
|
|
|
|
|
Company Profile Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Co.'s products include: EYLEA (aflibercept) Injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, diabetic retinopathy, and neovascular glaucoma; REGEN-COV, which is used for the treatment of COVID-19; and Kevzara (sarilumab) Solution for Subcutaneous Injection, which is used for the treatment of rheumatoid arthritis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
168,566 |
236,471 |
279,472 |
438,206 |
Total Sell Value |
$164,437,486 |
$226,505,895 |
$262,153,799 |
$373,147,368 |
Total People Sold |
8 |
14 |
16 |
18 |
Total Sell Transactions |
15 |
42 |
60 |
120 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Landry Robert E |
EVP Finance CFO |
|
2020-07-21 |
4 |
AS |
$647.50 |
$253,204 |
D/D |
(391) |
24,669 |
|
-20% |
|
Fenimore Christopher R. |
VP Controller |
|
2020-07-20 |
4 |
OE |
$52.03 |
$1,907,015 |
D/D |
12,224 |
21,210 |
|
- |
|
Fenimore Christopher R. |
VP Controller |
|
2020-07-20 |
4 |
D |
$655.57 |
$4,124,191 |
D/D |
(6,291) |
18,986 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2020-07-20 |
4 |
D |
$655.57 |
$4,859,740 |
D/D |
(7,413) |
25,060 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2020-07-20 |
4 |
OE |
$399.66 |
$4,177,160 |
D/D |
8,500 |
29,671 |
|
- |
|
Murphy Andrew J |
EVP Research |
|
2020-07-14 |
4 |
AS |
$614.62 |
$2,451,277 |
D/D |
(3,929) |
44,331 |
|
-18% |
|
Murphy Andrew J |
EVP Research |
|
2020-07-14 |
4 |
AS |
$630.77 |
$1,507,677 |
D/D |
(2,380) |
41,951 |
|
-18% |
|
Landry Robert E |
EVP Finance CFO |
|
2020-07-14 |
4 |
AS |
$640.50 |
$370,850 |
D/D |
(579) |
23,973 |
|
-18% |
|
Murphy Andrew J |
EVP Research |
|
2020-07-13 |
4 |
D |
$623.98 |
$4,175,050 |
D/D |
(6,691) |
48,260 |
|
- |
|
Murphy Andrew J |
EVP Research |
|
2020-07-13 |
4 |
OE |
$30.63 |
$398,190 |
D/D |
13,000 |
54,951 |
|
- |
|
Murphy Andrew J |
EVP Research |
|
2020-07-13 |
4 |
AS |
$620.64 |
$5,028,022 |
D/D |
(8,000) |
41,951 |
|
-16% |
|
Landry Robert E |
EVP Finance CFO |
|
2020-07-08 |
4 |
AS |
$634.14 |
$742,011 |
D/D |
(1,160) |
23,973 |
|
-16% |
|
Landry Robert E |
EVP Finance CFO |
|
2020-07-07 |
4 |
D |
$640.88 |
$7,267,579 |
D/D |
(11,340) |
25,133 |
|
- |
|
Landry Robert E |
EVP Finance CFO |
|
2020-07-07 |
4 |
OE |
$399.66 |
$6,555,850 |
D/D |
12,500 |
27,152 |
|
- |
|
Zoghbi Huda Y |
Director |
|
2020-07-07 |
4 |
AS |
$650.00 |
$1,108,900 |
D/D |
(1,706) |
643 |
|
-13% |
|
Zoghbi Huda Y |
Director |
|
2020-07-07 |
4 |
OE |
$391.92 |
$668,616 |
D/D |
1,706 |
2,349 |
|
- |
|
Sing George L |
Director |
|
2020-07-07 |
4 |
AS |
$650.00 |
$1,950,474 |
I/I |
(3,000) |
4,700 |
|
-13% |
|
Sing George L |
Director |
|
2020-07-07 |
4 |
AS |
$650.00 |
$4,875,000 |
D/D |
(7,500) |
115,415 |
|
-13% |
|
Sing George L |
Director |
|
2020-07-07 |
4 |
OE |
$33.42 |
$250,650 |
D/D |
7,500 |
122,915 |
|
- |
|
Vagelos P Roy |
Director |
|
2020-07-06 |
4 |
GD |
$0.00 |
$0 |
I/I |
341 |
143,559 |
|
- |
|
Brown Michael S |
Director |
|
2020-07-01 |
4 |
AS |
$601.70 |
$2,195,342 |
D/D |
(3,613) |
643 |
|
-7% |
|
Brown Michael S |
Director |
|
2020-07-01 |
4 |
OE |
$413.33 |
$1,493,361 |
D/D |
3,613 |
4,256 |
|
- |
|
Ryan Arthur F |
Director |
|
2020-07-01 |
4 |
AS |
$602.80 |
$60,970 |
D/D |
(100) |
28,643 |
|
-7% |
|
Sing George L |
Director |
|
2020-06-29 |
4 |
AS |
$606.80 |
$1,826,721 |
I/I |
(3,000) |
6,200 |
|
-7% |
|
Landry Robert E |
EVP Finance CFO |
|
2020-06-23 |
4 |
AS |
$624.65 |
$323,212 |
D/D |
(512) |
24,373 |
|
-11% |
|
1366 Records found
|
|
Page 27 of 55 |
|
|